Stiles Financial Services Inc increased its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,640 shares of the medical research company’s stock after acquiring an additional 350 shares during the quarter. Stiles Financial Services Inc’s holdings in Edwards Lifesciences were worth $549,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of EW. Sequoia Financial Advisors LLC lifted its stake in shares of Edwards Lifesciences by 11.4% in the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock worth $1,081,000 after acquiring an additional 941 shares in the last quarter. Zions Bancorporation N.A. lifted its stake in shares of Edwards Lifesciences by 34.7% in the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock worth $204,000 after acquiring an additional 448 shares in the last quarter. Covestor Ltd lifted its stake in shares of Edwards Lifesciences by 18.2% in the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock worth $144,000 after acquiring an additional 188 shares in the last quarter. Mather Group LLC. lifted its stake in shares of Edwards Lifesciences by 53.5% in the first quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock worth $846,000 after acquiring an additional 2,503 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in Edwards Lifesciences by 3.1% in the first quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock valued at $77,173,000 after buying an additional 19,798 shares during the last quarter. Institutional investors and hedge funds own 79.78% of the company’s stock.

Get Edwards Lifesciences alerts:

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 6,421 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $79.30, for a total value of $509,185.30. Following the completion of the sale, the insider now directly owns 213,794 shares in the company, valued at $16,953,864.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Catherine M. Szyman sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $85.81, for a total value of $429,050.00. Following the completion of the sale, the vice president now directly owns 35,056 shares in the company, valued at $3,008,155.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 6,421 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $79.30, for a total value of $509,185.30. Following the completion of the sale, the insider now owns 213,794 shares of the company’s stock, valued at $16,953,864.20. The disclosure for this sale can be found here. Insiders sold 159,025 shares of company stock worth $13,629,195 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on EW shares. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $75.00 to $87.00 in a report on Monday, April 24th. Mizuho boosted their price objective on Edwards Lifesciences from $95.00 to $102.00 in a report on Monday, July 17th. Jefferies Financial Group boosted their price objective on Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a report on Tuesday, July 25th. Morgan Stanley reissued an “overweight” rating and issued a $102.00 price objective on shares of Edwards Lifesciences in a report on Friday, July 14th. Finally, StockNews.com started coverage on Edwards Lifesciences in a report on Thursday, August 17th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $92.68.

Check Out Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Stock Performance

EW stock traded down $0.52 on Tuesday, reaching $75.81. The company’s stock had a trading volume of 1,392,318 shares, compared to its average volume of 3,157,038. Edwards Lifesciences Co. has a 52 week low of $67.13 and a 52 week high of $98.35. The company has a market capitalization of $46.09 billion, a P/E ratio of 33.77, a price-to-earnings-growth ratio of 4.13 and a beta of 1.02. The firm has a fifty day moving average of $87.24 and a two-hundred day moving average of $84.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.15 and a quick ratio of 2.30.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Edwards Lifesciences had a return on equity of 25.43% and a net margin of 24.56%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.51 billion. During the same period in the prior year, the company posted $0.63 EPS. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. As a group, analysts predict that Edwards Lifesciences Co. will post 2.55 EPS for the current fiscal year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Stories

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.